Literature DB >> 21435416

Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group.

Craig S Kitchens1, Doruk Erkan, Leonardo R Brandão, Susan Hahn, Andra H James, Roshni Kulkarni, Margaret Pericak-Vance, Jeffery Vance, Thomas L Ortel.   

Abstract

Physicians periodically encounter patients with an extraordinarily accelerated course of hypercoagulability who develop thromboses in multiple organ systems over days to weeks. Such patients may harbor underlying hypercoagulable clinical conditions, but their clinical course sets them apart from most patients with similar risk factors. Underlying triggers of "thrombotic storm" include pregnancy, inflammation, trauma, surgery, and infection. Aggressive anticoagulant therapy may control thrombotic storm, yet thrombotic storm may resume with even brief interruptions of anticoagulant therapy. The authors of this communication formed the Thrombotic Storm Study Group in order to identify clinical characteristics of such patients, thus constructing preliminary criteria to better define, identify, and study the course of patients deemed to have thrombotic storm. The characteristics culled from these 10 patients are: younger age (oldest was 38 years old at time of presentation); at least 2 arterial or venous (or both) thromboembolic events, typically in unusual sites with or without microangiopathy; unexplained recurrence; and frequently proceeded by a trigger. The following characteristics were not used in defining thrombotic storm: underlying malignancies; use of acute myocardial infarction as a defining arterial event in the setting of established coronary artery disease; use of cocaine; thrombotic complications expected with various intravascular devices; known paroxysmal nocturnal hemoglobinuria or myeloproliferative disorders; severe trauma; and premorbid conditions.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435416     DOI: 10.1016/j.amjmed.2010.10.018

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Top 10 clinical research developments in antiphospholipid syndrome.

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

2.  Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead.

Authors:  Holly N Cukier; Jimmy El Hokayem; Derek M Dykxhoorn
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-10-25

3.  Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.

Authors:  Ziyang Liu; Merry Markham; Molly W Mandernach
Journal:  BMJ Case Rep       Date:  2019-03-14

4.  Accelerated arterial and venous clots in a young pregnant woman: a saga of thrombotic storm.

Authors:  Madan Raj Aryal; Madan Badal; Naresh Bhandari; Vijaya Raj Bhatt
Journal:  BMJ Case Rep       Date:  2013-05-27

Review 5.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.

Authors:  Cassyanne L Aguiar; Doruk Erkan
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

6.  Lethal End of Spectrum of Clots-Thrombotic Storm.

Authors:  Muhammad Asim Rana; Ahmed F Mady; Abdullah Ali Lashari; Rehab Eltreafi; Nicola Fischer-Orr; Kamal Naser
Journal:  Case Rep Crit Care       Date:  2018-05-27

7.  COVID-19 Infection: A Sparked Ignition to a Thrombotic Storm.

Authors:  Yixin Zhang; Melissa Oye; Michael Omar
Journal:  Cureus       Date:  2022-07-19

8.  Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity.

Authors:  Janette Bester; Etheresia Pretorius
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

9.  Acute syndrome of pan-epidermolysis and thrombotic storm arising in a patient with systemic lupus erythematosus.

Authors:  Elise Burger; Darlene Gou; Travis Vandergriff; Arturo Dominguez; Melissa Mauskar
Journal:  JAAD Case Rep       Date:  2018-10-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.